THE DEFINITIVE GUIDE TO TRASTUZUMAB DOSING

The most under-investigated “driving forces” linked to trastuzumab resistance is PTEN. Nagata et al. (2004) documented which the loss of PTEN was noticed in 36% of HER2-optimistic primary breast tumor specimens from sufferers with stage IV disease. Additionally, Additionally they confirmed that individuals with PTEN-deficient tumors experienced